Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Therapy for organic erectile dysfunction].

A J Becker1, M Mayer, C G Stief

  • 1Urologische Klinik und Poliklinik, LMU, München. margit.mayer2@med.uni-muenchen.de

Der Urologe. Ausg. A
|September 10, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dynamic phenotypic shifts and M2 receptor downregulation in bladder smooth muscle cells induced by mirabegron.

Frontiers in pharmacology·2024
Same author

[Urinary diversion for acute epididymitis : Transurethral or suprapubic catheter?]

Urologie (Heidelberg, Germany)·2022
Same author

Optical analysis of glutamate spread in the neuropil.

Cerebral cortex (New York, N.Y. : 1991)·2022
Same author

[Enhanced Recovery After Surgery (ERAS®) after radical cystectomy-current data].

Der Urologe. Ausg. A·2021
Same author

<sup>18</sup>F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results.

European journal of nuclear medicine and molecular imaging·2020
Same author

[The role of the microbiome in urology].

Der Urologe. Ausg. A·2020
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
See all related articles

Erectile dysfunction (ED) is common in older men and impacts quality of life. Effective treatments range from oral medications like PDE-5 inhibitors to devices and implants, with new therapies on the horizon.

Area of Science:

  • Urology
  • Andrology
  • Men's Health

Context:

  • Erectile dysfunction (ED) is a prevalent condition, affecting approximately 50% of men in their 70s.
  • ED is linked to various comorbidities and significantly diminishes patient and partner quality of life.

Purpose:

  • To outline the diagnostic work-up for erectile dysfunction.
  • To review current and emerging therapeutic strategies for managing ED.

Summary:

  • Standard ED diagnosis involves medical/psychosexual history, physical exam, and lab tests.
  • First-line treatment includes oral phosphodiesterase-5 (PDE-5) inhibitors (sildenafil, tadalafil, vardenafil).
  • Second-line options are local pharmacotherapy, followed by vacuum devices and penile implants as third-line treatments.

Related Experiment Videos

Impact:

  • Optimizing ED therapy requires individualized approaches considering patient circumstances.
  • Established treatments offer high patient satisfaction.
  • Emerging therapies like anti-serotoninergic substrates and growth hormone show future promise for ED management.